Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mariko Riley"'
Autor:
Mariko Riley, Katie Stamp, Xinde Zheng, Yan Ren, Kate Blease, Chin-Chun Lu, Julia Hui, Lawrence G Hamann, Philip P Chamberlain, Gang Lu, Polat Abdubek, Mary E Matyskiela, Gondi Kumar, Maria Wang, Wei Fang, Aaron Carpenter, Thomas Clayton, Clifton Drew, Suzana Couto, Chung-Wein Lee, Mark Rolfe, Rupert Vessey, James Hartke
Publikováno v:
Nature Chemical Biology. 14:981-987
Targeted protein degradation via small-molecule modulation of cereblon offers vast potential for the development of new therapeutics. Cereblon-binding therapeutics carry the safety risks of thalidomide, which caused an epidemic of severe birth defect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29f5299ace6c6c8aa0af7dbee0692fbc
https://doi.org/10.1038/s41589-018-0129-x
https://doi.org/10.1038/s41589-018-0129-x
Autor:
Yoshitaka Satoh, Gilles Carmel, Frans Baculi, Peter H. Schafer, Laurie LeBrun, Matt Hickman, Thomas O. Daniel, Brian E. Cathers, James Carmichael, Godrej Khambatta, Hon-Wah Man, Mary E Matyskiela, Philip P Chamberlain, Weihong Zhang, Mariko Riley, George W. Muller, Barbra Pagarigan, Gang Lu, Chin-Chun Lu
Publikováno v:
Journal of Medicinal Chemistry. 61:535-542
The drugs lenalidomide and pomalidomide bind to the protein cereblon, directing the CRL4-CRBN E3 ligase toward the transcription factors Ikaros and Aiolos to cause their ubiquitination and degradation. Here we describe CC-220 (compound 6), a cereblon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba3ec7b8486c677242241f929022984b
https://doi.org/10.1021/acs.jmedchem.6b01921
https://doi.org/10.1021/acs.jmedchem.6b01921
Autor:
Alexander L. Ruchelman, Jack Houston, Nai-Yu Wang, Lyn'Al Nosaka, Antonia Lopez-Girona, Takumi Ito, Gilles Carmel, Mary E Matyskiela, Wei Fang, Derek Nguyen, Philip P Chamberlain, Thomas O. Daniel, Karen Miller, Chin-Chun Lu, Barbra Pagarigan, Svetlana Gaidarova, Gang Lu, Shuichan Xu, James Carmichael, Tam Tran, Gabriel C. Lander, Mariko Riley, Brian E. Cathers, Hiroshi Handa
Publikováno v:
Nature. 535:252-257
Immunomodulatory drugs bind to cereblon (CRBN) to confer differentiated substrate specificity on the CRL4(CRBN) E3 ubiquitin ligase. Here we report the identification of a new cereblon modulator, CC-885, with potent anti-tumour activity. The anti-tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91e627c880e58840f87057e76f90aa5d
https://doi.org/10.1038/nature18611
https://doi.org/10.1038/nature18611
Autor:
Philip P Chamberlain, Maria Wang, Yoshinori Hirano, Brian E. Cathers, Gilles Carmel, Toshio Hakoshima, Hiroshi Handa, Barbra Pagarigan, Emily Rychak, Yan J Ren, Barbara Chie-Leon, Silvia L. Delker, Laura G. Corral, Tomoyuki Mori, Takumi Ito, Thomas O. Daniel, Antonia Lopez-Girona, Karen Miller, Hideki Ando, Mariko Riley
Publikováno v:
Nature Structural & Molecular Biology. 21:803-809
The Cul4-Rbx1-DDB1-Cereblon E3 ubiquitin ligase complex is the target of thalidomide, lenalidomide and pomalidomide, therapeutically important drugs for multiple myeloma and other B-cell malignancies. These drugs directly bind Cereblon (CRBN) and pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b131abf0f427feaba8ec6b36dad4572
https://doi.org/10.1038/nsmb.2874
https://doi.org/10.1038/nsmb.2874
Autor:
Aaron A. Priest, Frank Stappenbeck, Wei Xiao, Huang Danwen, Mariko Riley, Michael E. Jung, Matt Epperson, Francine S. Farouz, Khanhlinh Nguyen, R. Scott Thies
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 22:5893-5897
Localized induction of bone formation is essential during orthopedic procedures that involve skeletal repair, such as surgical treatment of non-union bone fractures and degenerative disk disease. Herein we disclose the synthesis and biological evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0137838847e469b757249f6aa015edf
https://doi.org/10.1016/j.bmcl.2012.07.073
https://doi.org/10.1016/j.bmcl.2012.07.073
Autor:
Tam Tran, Gabriel C. Lander, James Carmichale, Thomas O. Daniel, Svetlana Gaidarova, Mary E Matyskiela, Lyn'Al Nosaka, Antonia Lopez-Girona, Takumi Ito, Alexander L. Ruchelman, Gilles Carmel, Jack Houston, Brian E. Cathers, Philip P Chamberlain, Wei Fang, Hiroshi Handa, Derek Nguyen, Mariko Riley, Karen Miller, Shuichan Xu, Barbra Pagarigan, Gang Lu, Chin-Chu Lu, Nai-Yu Wang
Publikováno v:
Cancer Research. 77:SY37-02
The protein cereblon is part of the CRL4-CRBN E3 ubiquitin ligase complex, and has been shown to be the molecular target for the drugs lenalidomide and pomalidomide. These drugs bind to the surface of cereblon, triggering the recruitment of substrate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2acec69e19aebcc0985034bd9ab2603b
https://doi.org/10.1158/1538-7445.am2017-sy37-02
https://doi.org/10.1158/1538-7445.am2017-sy37-02